Loading...

Therapeutic cancer vaccines and combination immunotherapies involving vaccination

Recent US Food and Drug Administration approvals of Provenge(®) (sipuleucel-T) as the first cell-based cancer therapeutic factor and ipilimumab (Yervoy(®)/anticytotoxic T-lymphocyte antigen-4) as the first “checkpoint blocker” highlight recent advances in cancer immunotherapy. Positive results of th...

Full description

Saved in:
Bibliographic Details
Published in:Immunotargets Ther
Main Authors: Nguyen, Trang, Urban, Julie, Kalinski, Pawel
Format: Artigo
Language:Inglês
Published: Dove Medical Press 2014
Subjects:
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4918241/
https://ncbi.nlm.nih.gov/pubmed/27471705
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/ITT.S40264
Tags: Add Tag
No Tags, Be the first to tag this record!